NEW YORK, NY / ACCESSWIRE / April 12, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Uxin Limited (NASDAQGS: UXIN)
Class Period: Pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the June 27, 2018 initial public offering
Lead Plaintiff Deadline: April 12, 2019
The Registration Statement was materially false and misleading and omitted to state that: (1) Uxin was likely to stop providing complementary services such as inspections to its customers; (2) instead, Uxin would connect consumers to dealers who would provide such complementary services; (3) as a result, Uxin's 2B business would be materially impacted; and (4) consequently, Defendants' statements in the Registration Statement regarding Uxin’s business, operations, and prospects, were materially false and/or misleading.
Get additional information about the UXIN lawsuit: http://www.kleinstocklaw.com/pslra-1/uxin-limited-loss-submission-form?id=1087&from=1
Diplomat Pharmacy, Inc. (NYSE: DPLO)
Class Period: February 26, 2018 to February 21, 2019
Lead Plaintiff Deadline: April 25, 2019
The complaint alleges that throughout the class period Diplomat Pharmacy, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Diplomat had downplayed its success in integrating and growing its PBM business, which included LDI Integrated and National Pharmaceutical, two companies Diplomat had acquired in late 2017; (2) consequently, Diplomat would need to record a non-cash impairment charge upwards of approximately $630 million relating to its PBM business and these 2017 acquisitions; (3) due to the foregoing, Diplomat would withdraw its preliminary 2019 full-year outlook issued less than seven weeks prior; and (4) as a result, defendants' statements about Diplomat's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Get additional information about the DPLO lawsuit: http://www.kleinstocklaw.com/pslra-1/diplomat-pharmacy-inc-loss-submission-form?id=1087&from=1
Amarin Corporation (NASDAQGM: AMRN)
Class Period: September 24, 2018 to November 9, 2018
Lead Plaintiff Deadline: April 23, 2019
The complaint alleges that during the class period Amarin Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the top-line results Amarin touted about its REDUCE-IT trial for Vascepa were not as positive as the company represented; (2) the placebo given to patients in the control arm of REDUCE-IT may have increased the incidence of cardiovascular events in those patients; (3) as a result, Amarin's public statements were materially false and misleading at all relevant times.
Get additional information about the AMRN lawsuit: http://www.kleinstocklaw.com/pslra-1/amarin-corporation-loss-submission-form?id=1087&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm
View source version on accesswire.com:
https://www.accesswire.com/541896/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-UXIN-DPLO-and-AMRN
